Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$75.99

-0.65 (-0.85%)

06:49
11/23/16
11/23
06:49
11/23/16
06:49

Eli Lilly's Phase 3 solanezumab clinical trial did not meet primary endpoint

Eli Lilly announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease. Patients treated with solanezumab did not experience a statistically significant slowing in cognitive decline compared to patients treated with placebo, as measured by the ADAS-Cog14. While the study results, including many secondary clinical endpoints, directionally favored solanezumab, the magnitudes of treatment differences were small. There were no new safety signals identified in the study. Lilly will not pursue regulatory submissions for solanezumab for the treatment of mild dementia due to Alzheimer's disease. Lilly will work with investigators to appropriately conclude the open-label extensions for EXPEDITION, EXPEDITION2 and EXPEDITION3. The EXPEDITION3 study outcome is expected to result in a Q4 charge of approximately $150M pre-tax, or approximately 9c per share after-tax.

  • 04

    Dec

LLY Eli Lilly
$75.99

-0.65 (-0.85%)

11/03/16
BMOC
11/03/16
NO CHANGE
BMOC
Eli Lilly factored pricing pressure into guidance, says BMO Capital
After meeting with Eli Lilly, BMO Capital analyst Alex Arfaei reports that the company seemed surprised at the intensity of investors' concerns about pricing pressure on it. The analyst says that the company anticipated pricing pressure and factored it into its guidance. The analyst keeps a $91 price target and an Outperform rating on the shares.
11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.
11/11/16
JEFF
11/11/16
NO CHANGE
Target $100
JEFF
Buy
Jefferies bullish on Lilly regardless of Alzheimer's data
Jefferies analyst Jeffrey Holford believes shares of Eli Lilly "can work over time" regardless of Alzheimer's disease drug solanezumab's Phase III study outcome. The analyst, however, says he has enough confidence to recommend Lilly shares ahead of the EXPEDITION3 data readout. Holford increased his base case solanezumab peak sales to $5B. He says Lilly remains one of his top picks with a Buy rating and $100 price target.
11/15/16
JPMS
11/15/16
NO CHANGE
Target $95
JPMS
Overweight
JPMorgan sees favorable risk/reward for Lilly into Alzheimer's data
JPMorgan analyst Chris Schott sees a favorable risk/reward profile for shares of Eli Lilly into the solanezumab data for Alzheimer's, which is expected by year-end. Favorable data from the EXPEDITION-3 trial would represent a catalyst not just for Lilly and other Alzheimer's associated names but for the biopharma space as a whole, Schott tells investors in a research note. The analyst expects 20%-plus share upside in the event the trial is successful on both primary and secondary endpoints. He assigns a 10%-20% probability to this outcome. Schott sees 10%-20% share upside for Lilly should the study hit on its primary but only shows a trend on secondary endpoints. He assigns a 50%-60% probability for this outcome. The analyst also sees a 10% move to the downside if the study fails both endpoints, an outcome he assigns a 20% probability. Schott reiterates an Overweight rating on Lilly with a $95 price target. He believes Lilly's "diverse range of pipeline opportunities" largely supports the valuation at current levels.

TODAY'S FREE FLY STORIES

RGNX

Regenxbio

$29.05

-0.75 (-2.52%)

07:18
09/20/17
09/20
07:18
09/20/17
07:18
Hot Stocks
Regenxbio completes dosing of first cohort in Phase I clinical trial of RGX-314 »

Regenxbio announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

AMZN

Amazon.com

$969.86

-4.33 (-0.44%)

, BABA

Alibaba

$180.07

0.09 (0.05%)

07:17
09/20/17
09/20
07:17
09/20/17
07:17
Periodicals
Amazon takes on rivals in India digital payments market, The Information says »

Amazon (AMZN) has taken…

AMZN

Amazon.com

$969.86

-4.33 (-0.44%)

BABA

Alibaba

$180.07

0.09 (0.05%)

SFTBF

SoftBank

$82.75

4.45 (5.68%)

GOOG

Alphabet

$921.81

6.81 (0.74%)

GOOGL

Alphabet Class A

$936.86

7.11 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Nov

SBNY

Signature Bank

$120.15

0.21 (0.18%)

07:16
09/20/17
09/20
07:16
09/20/17
07:16
Downgrade
Signature Bank rating change  »

Signature Bank downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HK

Halcon Resources

$6.23

-0.19 (-2.96%)

07:14
09/20/17
09/20
07:14
09/20/17
07:14
Hot Stocks
Halcon Resources announces sale of non-operated Williston Basin assets »

Halcon Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

07:14
09/20/17
09/20
07:14
09/20/17
07:14
Recommendations
Bed Bath & Beyond analyst commentary  »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$32.49

-0.03 (-0.09%)

07:12
09/20/17
09/20
07:12
09/20/17
07:12
Conference/Events
Cisco management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

  • 25

    Sep

  • 26

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

  • 22

    Oct

  • 15

    Nov

AVEO

AVEO Oncology

$3.84

0.07 (1.86%)

, BMY

Bristol-Myers

$62.93

0.23 (0.37%)

07:12
09/20/17
09/20
07:12
09/20/17
07:12
Hot Stocks
AVEO Oncology, EUSA Pharma announce TiNivo combination study opt-in »

AVEO Oncology (AVEO) and…

AVEO

AVEO Oncology

$3.84

0.07 (1.86%)

BMY

Bristol-Myers

$62.93

0.23 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 18

    Oct

  • 26

    Oct

  • 09

    Nov

  • 05

    Mar

ADBE

Adobe

$156.60

0.83 (0.53%)

07:12
09/20/17
09/20
07:12
09/20/17
07:12
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

SUPN

Supernus

$38.05

-11.6 (-23.36%)

07:11
09/20/17
09/20
07:11
09/20/17
07:11
Recommendations
Supernus analyst commentary  »

Jefferies still sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

WFC

Wells Fargo

$53.36

0.65 (1.23%)

07:10
09/20/17
09/20
07:10
09/20/17
07:10
Periodicals
Wells Fargo general counsel aims to clean up reputation, Reuters reports »

Wells Fargo general…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 12

    Oct

  • 22

    Oct

  • 29

    Nov

  • 15

    Jan

ELY

Callaway Golf

$14.14

0.12 (0.86%)

07:09
09/20/17
09/20
07:09
09/20/17
07:09
Recommendations
Callaway Golf analyst commentary  »

Callaway Golf EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$252.46

-0.62 (-0.24%)

07:09
09/20/17
09/20
07:09
09/20/17
07:09
Recommendations
Boeing analyst commentary  »

Boeing price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

MTCH

Match Group

$23.45

-0.02 (-0.09%)

07:08
09/20/17
09/20
07:08
09/20/17
07:08
Recommendations
Match Group analyst commentary  »

Match Group price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIS

General Mills

$55.38

-1.05 (-1.86%)

07:08
09/20/17
09/20
07:08
09/20/17
07:08
Hot Stocks
Breaking Hot Stocks news story on General Mills »

General Mills down 4.3%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

KPTI

Karyopharm

$10.52

-0.34 (-3.13%)

07:07
09/20/17
09/20
07:07
09/20/17
07:07
Hot Stocks
Karyopharm: 'successful' outcome from Phase 2 portion of Phase 2/3 SEAL study »

Karyopharm reported a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

GIS

General Mills

$55.38

-1.05 (-1.86%)

07:05
09/20/17
09/20
07:05
09/20/17
07:05
Hot Stocks
General Mills CEO says FY18 priority is 'strengthening our topline performance' »

"Our number one…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

SNY

Sanofi

$49.10

0.46 (0.95%)

, ALNY

Alnylam

$75.04

-0.96 (-1.26%)

07:05
09/20/17
09/20
07:05
09/20/17
07:05
Hot Stocks
Sanofi and Alnylam report topline results of patisiran in ATTR amyloidosis »

Sanofi's (SNY)…

SNY

Sanofi

$49.10

0.46 (0.95%)

ALNY

Alnylam

$75.04

-0.96 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

ADBE

Adobe

$156.60

0.83 (0.53%)

07:04
09/20/17
09/20
07:04
09/20/17
07:04
Recommendations
Adobe analyst commentary  »

Adobe near-term weakness…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

WDC

Western Digital

$89.92

0.74 (0.83%)

07:04
09/20/17
09/20
07:04
09/20/17
07:04
Technical Analysis
Technical View: Western Digital falls as Toshiba selects Bain-led group as buyer »

Toshiba (TOSBF, TOSYY)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIS

General Mills

$55.38

-1.05 (-1.86%)

07:04
09/20/17
09/20
07:04
09/20/17
07:04
Hot Stocks
General Mills CEO says 'confident in improved momentum' for rest of year »

CEO Harmening said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

SIX

Six Flags

$56.75

-0.32 (-0.56%)

07:03
09/20/17
09/20
07:03
09/20/17
07:03
Hot Stocks
Six Flags says no expected material impact from Mexico earthquake »

Six Flags Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

PG

Procter & Gamble

$94.17

1.02 (1.10%)

07:03
09/20/17
09/20
07:03
09/20/17
07:03
Hot Stocks
Procter & Gamble: Peltz 'lacks specific qualities' P&G seeking in board members »

The Procter & Gamble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIS

General Mills

$55.38

-1.05 (-1.86%)

07:03
09/20/17
09/20
07:03
09/20/17
07:03
Hot Stocks
General Mills reports Q1 gross margin down 150 bps to 34.8% »

Gross margin decreased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

07:02
09/20/17
09/20
07:02
09/20/17
07:02
General news
MBA Mortgage Applications Composite Index data reported »

Week of 9/15 MBA Mortgage…

IDN

Intellicheck

07:02
09/20/17
09/20
07:02
09/20/17
07:02
Initiation
Intellicheck initiated  »

Intellicheck initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.